- UroMems raised $60 million from Ajax Health Fund I, marking its largest funding round to date.
- The financing will support pivotal clinical trials of the UroActive implant in the U.S. and France before regulatory submissions.
- UroActive is the first automated artificial urinary sphincter designed to treat stress urinary incontinence without manual adjustments.
Grenoble-based UroMems has secured a $60 million strategic investment from Ajax Health to expand clinical trials and prepare for regulatory approvals in the U.S. and Europe.
The round is the company’s largest fundraising to date and comes less than a year after its $47 million Series C financing in June 2024.
Founded in 2011 by Hamid Lamraoui, PhD, Prof. Pierre Mozer, MD, PhD (Sorbonne & La Pitié), and Stéphane Lavalleé, UroMems develops implantable mechatronics technology for stress urinary incontinence, known as SU. It is said that this condition affects an estimated 40 million Americans and 90 million Europeans.
“Ajax Health Fund I’s support strengthens our position as we near FDA PMA submission and commercialisation,” said Lamraoui. “We believe UroActive can transform SUI treatment and bring a better option to patients and physicians.”
Its lead product, UroActive, is an automated artificial urinary sphincter powered by a MyoElectroMechanical System (MEMS). The implant is placed around the urethral duct and automatically adjusts according to patient activity, removing the need for manual operation. The device is designed for both men and women suffering from sphincter insufficiency.
The company’s technology platform is protected by more than 200 granted patents. UroMems is competing with traditional artificial urinary sphincter manufacturers including Boston Scientific and Zephyr Surgical Implants, whose devices still rely on manual activation.
David Beylik, partner at Ajax Health, says, “Combining our industry experience and capital with the UroMems team, we believe that the UroActive smart implant has the potential to become the l standard of care for SUI treatment.”
The latest financing will support the ongoing SOPHIA2 clinical trial taking place across 21 investigational centres in the U.S. and France. Data from the study will be used for regulatory submissions in both markets.
David Beylik, partner at Ajax Health, says, “Combining our industry experience and capital with the UroMems team, we believe that the UroActive smart implant has the potential to become the l standard of care for SUI treatment.”
